Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight

Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis

We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely

Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next

Vor Bio To Participate in Upcoming September Conferences

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus